Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results.
about
Uncharged isocoumarin-based inhibitors of urokinase-type plasminogen activator.Prediction of metalloproteinase family based on the concept of Chou's pseudo amino acid composition using a machine learning approach.Exploring QSAR and pharmacophore mapping of structurally diverse selective matrix metalloproteinase-2 inhibitors.Matrix metalloproteases and tissue inhibitors of metalloproteinases in medial plica and pannus-like tissue contribute to knee osteoarthritis progression.Recent advances in MMP inhibitor design.Therapeutic potential of sulfamides as enzyme inhibitors.Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases.Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.Expression of catalytically active matrix metalloproteinase-1 in dermal fibroblasts induces collagen fragmentation and functional alterations that resemble aged human skin.Matrix metalloproteinases: drug targets for myocardial infarction.Recent progress in therapeutic applications of chalcones.Pigment epithelium-derived factor as a natural matrix metalloproteinase inhibitor: a comparison with classical matrix metalloproteinase inhibitors used for cancer treatment.Have artificial neural networks met expectations in drug discovery as implemented in QSAR framework?New biochemical insight of conserved water molecules at catalytic and structural Zn2+ ions in human matrix metalloproteinase-I: a study by MD-simulation.Synthesis and structure-activity relationship of 3-hydroxypyridine-2-thione-based histone deacetylase inhibitors.Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase.Ruthenium(III) dimethyl sulfoxide pyridinehydroxamic acid complexes as potential antimetastatic agents: synthesis, characterisation and in vitro pharmacological evaluation.MMPs/TIMPs imbalances in the peripheral blood and cerebrospinal fluid are associated with the pathogenesis of HIV-1-associated neurocognitive disorders.Synthesis and structural characterisation of bismuth(III) hydroxamates and their activity against Helicobacter pylori.A QSAR Study of Matrix Metalloproteinases Type 2 (MMP-2) Inhibitors with Cinnamoyl Pyrrolidine Derivatives.The sulfamide motif in the design of enzyme inhibitors.Selective inhibition of carotenoid cleavage dioxygenases: phenotypic effects on shoot branching.A profiling platform for the identification of selective metalloprotease inhibitors.An insight to conserved water molecular dynamics of catalytic and structural Zn(+2) ions in matrix metalloproteinase 13 of human.A combined molecular modeling study on gelatinases and their potent inhibitors.In silico study combining docking and QSAR methods on a series of matrix metalloproteinase 13 inhibitors.
P2860
Q33233428-B719BF85-EC70-4F16-AE18-8AE71A6DC6B5Q34238445-2604A2D7-E076-4938-81B0-008B0110A9E6Q34985930-10DC11CB-90ED-4AEF-A2AA-2A2007210075Q35041457-82A1CD87-02B1-4B6A-BC64-11E8696DFB07Q36471137-39500764-1556-46DC-A2E8-103E1C8BCE68Q36482621-CA0CF4A5-ACBA-494C-8C90-6F2D8AB88D78Q36644577-337E8FBC-4257-445B-B21B-6B43941BDC44Q36836612-D18EF15B-BC92-4759-8886-680EC204B0F7Q37024770-F01915D8-254E-400A-8961-603059F75230Q37082348-AB0A122F-8081-4E05-92F7-D7F779393C34Q37308645-EF31A556-B57A-4385-897C-AB7AD628F8C0Q37895269-845D43D8-F724-4B83-AB99-A5C4A111C6BCQ38201795-0CF820A9-2DEC-4222-B7A9-55744F5B86F0Q38826551-89D6F076-5B0A-400B-BAC7-3C3F3B154392Q38978663-E95BEEF6-4F70-4835-B559-083080F61DBAQ39049177-80702AA5-9090-4770-A17D-7E95769B4E47Q39515111-9B58E351-0AD7-4C1E-821E-9D6A9A13EE96Q40027116-590D9477-4198-4E01-8B93-D915B484413EQ40219795-5F0CEA9E-EB0D-4329-81A9-E88762770B38Q41008910-B3B39157-BD0E-479F-95FD-704A9A3F3A23Q41843257-00F02359-D3D6-462A-8101-AD0D8A1B80AFQ43168863-76E08D15-2CEF-470C-A71E-6AE42154207FQ43179967-A38CDFFF-331B-4A80-927F-F882AA1B8941Q43204016-42D9738D-B304-4193-B329-CFD1C84D9DE8Q45862917-A969C12B-4F39-45C3-8D20-987722158FE2Q47890008-AC367D72-D501-4B34-8A43-69DE309A5F5FQ51017366-8865DE65-D8A7-4A6D-B175-DBD729A98460
P2860
Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Matrix metalloproteinase inhib ...... e mapping and (Q)SARs results.
@ast
Matrix metalloproteinase inhib ...... e mapping and (Q)SARs results.
@en
type
label
Matrix metalloproteinase inhib ...... e mapping and (Q)SARs results.
@ast
Matrix metalloproteinase inhib ...... e mapping and (Q)SARs results.
@en
prefLabel
Matrix metalloproteinase inhib ...... e mapping and (Q)SARs results.
@ast
Matrix metalloproteinase inhib ...... e mapping and (Q)SARs results.
@en
P2093
P921
P356
P1476
Matrix metalloproteinase inhib ...... e mapping and (Q)SARs results.
@en
P2093
Hadjipavlou-Litina DJ
Kontogiorgis CA
Papaioannou P
P304
P356
10.2174/0929867053363243
P577
2005-01-01T00:00:00Z